You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Secondary Progressive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mayzent Onboarding of Secondary Progressive Multiple Sclerosis

Completed
  • Secondary Progressive Multiple Sclerosis
    • Camperdown, New South Wales, Australia
    • +1 more
    Apr 19, 2023

    Multiple Sclerosis Trial (Frexalimab, Placebo, MRI contrast-enhancing agents)

    Not yet recruiting
    • Multiple Sclerosis
    • (no location specified)
    Nov 15, 2023

    Secondary-progressive Multiple Sclerosis Trial in Buffalo (Mayzent, Ocrevus)

    Recruiting
    • Secondary-progressive Multiple Sclerosis
    • Buffalo, New York
      University at Buffalo, Buffalo General Hospital
    Oct 10, 2022

    Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Trial in Warsaw (Cladribine Subcutaneous Injection, 0.9% Chloride

    Recruiting
    • Multiple Sclerosis, Secondary Progressive
    • Multiple Sclerosis
    • Cladribine Subcutaneous Injection
    • 0.9% Chloride Injection Sodium
    • Warsaw, Mazowieckie, Poland
      Institute of Psychiatry and Neurology
    Jul 26, 2023

    Multiple Sclerosis Trial (Siponimod)

    Available
    • Multiple Sclerosis
    • (no location specified)
    Sep 13, 2022

    Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Trial in Salt Lake City

    Recruiting
    • Secondary Progressive Multiple Sclerosis
    • +2 more
    • Ferumoxytol infusion
    • +2 more
    • Salt Lake City, Utah
      University of Utah Health Imaging and Neurosciences Center
    Jun 22, 2022

    Progressive Multiple Sclerosis Trial in Lille, Strasbourg (Placebo, Masitinib (4.5))

    Recruiting
    • Progressive Multiple Sclerosis
    • Placebo
    • Masitinib (4.5)
    • Lille, France
    • +1 more
    Jul 1, 2022

    Multiple Sclerosis (MS) Patients

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • +2 more
      • (no location specified)
      Dec 15, 2022

      Secondary Progressive Multiple Sclerosis (SPMS) Trial in Tel Aviv (SCM-010)

      Not yet recruiting
      • Secondary Progressive Multiple Sclerosis (SPMS)
      • SCM-010
      • Tel Aviv, Israel
        Tel Aviv Medical Center
      Oct 26, 2022

      Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis Trial (Intranasal Foralumab

      Withdrawn
      • Primary Progressive Multiple Sclerosis
      • +2 more
      • Intranasal Foralumab Solution
      • Placebo
      • (no location specified)
      Feb 14, 2022

      Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

      Not yet recruiting
      • Multiple Sclerosis
      • +2 more
      • KYV-101 anti-CD19 CAR-T cell therapy
      • Standard lymphodepletion regimen
      • Palo Alto, California
        Stanford Multiple Sclerosis Center
      Nov 13, 2023

      Secondary Progressive Multiple Sclerosis Trial in Germany (BAF312, Baseline disease modifying therapies (DMTs))

      Active, not recruiting
      • Secondary Progressive Multiple Sclerosis
      • BAF312
      • Baseline disease modifying therapies (DMTs)
      • Mittweida, Sachsen, Germany
      • +9 more
      Aug 9, 2022

      Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive

      Completed
      • Multiple Sclerosis, Relapsing-Remitting
      • +2 more
      • 18F-DPA-714 and 18F-FDG
      • Paris, France
      • +1 more
      Sep 14, 2022

      Multiple Sclerosis, Secondary Progressive Trial in Calgary (Hydroxychloroquine Pill, Indapamide Pill)

      Recruiting
      • Multiple Sclerosis, Secondary Progressive
      • Hydroxychloroquine Pill
      • Indapamide Pill
      • Calgary, Alberta, Canada
        Foothills Medical Centre
      May 16, 2022

      Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Trial in Tokyo (OCH-NCNP1, Placebo)

      Active, not recruiting
      • Multiple Sclerosis, Relapsing-Remitting
      • Multiple Sclerosis, Secondary Progressive
      • Tokyo, Japan
        National Center of Neurology and Psychiatry
      Sep 28, 2022

      Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple Sclerosis Trial in Belgium (Metformin

      Not yet recruiting
      • Multiple Sclerosis
      • +2 more
      • Metformin Hydrochloride 850 mg Oral Tablet
      • Placebo
      • Brugge, Belgium
      • +4 more
      May 30, 2023

      Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial in Los Angeles (Metformin 500 Mg Oral

      Recruiting
      • Secondary Progressive Multiple Sclerosis
      • Primary Progressive Multiple Sclerosis
      • Metformin 500 Mg Oral Tablet, up to 4 tablets a day
      • Placebo oral tablet identical to metformin, up to 4 tablets a day
      • Los Angeles, California
        University of California, Los Angeles
      May 2, 2022

      Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in San Francisco

      Recruiting
      • Multiple Sclerosis
      • +2 more
      • N-acetyl cysteine
      • Placebo
      • San Francisco, California
        University of California, San Francisco
      Mar 22, 2022

      Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Birmingham, Saint Louis (Glycemic

      Not yet recruiting
      • Relapsing Remitting Multiple Sclerosis
      • Secondary Progressive Multiple Sclerosis
      • Glycemic load
      • +2 more
      • Birmingham, Alabama
      • +1 more
      Jan 4, 2023

      Measuring Active Microglia in Progressive Multiple Sclerosis

      Completed
      • Secondary Progressive Multiple Sclerosis
      • [C11]PK-1195 PET scan
      • New York, New York
        Weill Cornell Medical College
      Jan 14, 2022

      Mayzent on SPMS Patients in a Long-term Non-interventional Study

      Recruiting
      • Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
      • Siponimod
      • Baden, Aargau, Switzerland
      • +8 more
      May 16, 2022

      Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

      Recruiting
      • Active Secondary Progressive Multiple Sclerosis
      • siponimod
      • Ancona, AN, Italy
      • +19 more
      Dec 27, 2022

      Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis Trial

      Active, not recruiting
      • Secondary Progressive Multiple Sclerosis
      • +2 more
      • Minneapolis, Minnesota
      • +2 more
      Mar 29, 2022

      Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Marseille, Rennes (Magnetic

      Recruiting
      • Multiple Sclerosis, Primary Progressive
      • Multiple Sclerosis, Secondary Progressive
      • Magnetic Resonance Imaging
      • +3 more
      • Marseille, France
      • +1 more
      Jan 14, 2022

      Multiple Sclerosis Trial in France (DMT withdrawal, DMT continuation)

      Recruiting
      • Multiple Sclerosis
      • DMT withdrawal
      • DMT continuation
      • Angers, France
      • +22 more
      Mar 25, 2022